Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Non-Current Deffered Revenue: 2014-2020

Historic Non-Current Deffered Revenue for KalVista Pharmaceuticals (KALV) over the last 3 years, with Jan 2020 value amounting to $2.5 million.

  • KalVista Pharmaceuticals' Non-Current Deffered Revenue fell 31.81% to $2.5 million in Q1 2020 from the same period last year, while for Jan 2020 it was $2.5 million, marking a year-over-year decrease of 31.81%. This contributed to the annual value of $3.3 million for FY2019, which is 69.23% down from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Non-Current Deffered Revenue stood at $2.5 million for Q1 2020, which was down 9.22% from $2.8 million recorded in Q4 2019.
  • Over the past 5 years, KalVista Pharmaceuticals' Non-Current Deffered Revenue peaked at $13.9 million during Q1 2018, and registered a low of $49,000 during Q1 2016.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $3.7 million (2019), whereas its average is $5.9 million.
  • Data for KalVista Pharmaceuticals' Non-Current Deffered Revenue shows a maximum YoY plummeted of 73.61% (in 2019) over the last 5 years.
  • Quarterly analysis of 4 years shows KalVista Pharmaceuticals' Non-Current Deffered Revenue stood at $49,000 in 2016, then reached $4.7 million in 2018, then tumbled by 41.03% to $2.8 million in 2019, then crashed by 31.81% to $2.5 million in 2020.
  • Its Non-Current Deffered Revenue was $2.5 million in Q1 2020, compared to $2.8 million in Q4 2019 and $2.9 million in Q3 2019.